Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 1 of 39  
 
STATISTICAL ANALYSIS PLAN  
 
 
Protocol 4658 -203 
 
An Open-Label, Multi -Center Study to Evaluate the Safety, Efficacy and 
Tolerability of Eteplirsen in Early -Stage Duchenne Muscular Dystrophy  
 
 
 
  
 
Sarepta Therapeutics, Inc.  
215 First Street  
Cambridge, MA 02142 USA 
 
        
 (Protocol version: Amendment 2,  08 June 2017) 
 
  
 Version: 1.0  
 Date: 11 February 2019  
   

PPD
PPD
PPD
PPD
PPDPPD
PPD
PPD
PPD
PPDPPD
PPD
PPD
PPD
PPD
PPDPPDPPDPPD
PPDPPD
PPD
PPD
P
PDPPD
PPD
PPD
PPDPPD
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI7$%/(2)&217(176
6,*1$785(3$*(   
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506   
 ,QWURGXFWLRQ   
 6WXG\2EMHFWLYHV   
  3ULPDU\2EMHFWLYHV   
  6HFRQGDU\2EMHFWLYHV   
  
  3KDUPDFRNLQHWLF2EMHFWLYHV   
 6WXG\'HVFULSWLRQ   
  6WXG\2YHUYLHZ   
  5DQGRPL]DWLRQRI0XVFOH%LRSV\6FKHGXOH   
  %OLQGLQJ   
  6WXG\(QGSRLQWVDQG2W KHU9DULDEOHV   
  6DIHW\(QGSRLQWV   
  6HFRQGDU\(QGSRLQWV   
  
  3KDUPDFRNLQHWLF(QGSRLQWV   
  6DPSOH6L]HDQG3RZHU   
  3ODQQHG$QDO\VHV   
  3HULRGLF6DIHW\'DWD5HYLHZV   
  )LQDO$QDO\VLV   
 *HQHUDO6WDWLVWLFDO0HWKRGVDQG&RQYHQWLRQV   
  *HQHUDO0HWKRGV   
  +DQGOLQJRI0LVVLQJ'DWD   
  ,PSXWDWLRQRI0LVVLQJ9DOXHV   
  +DQGOLQJRI,QFRPSOHWH'DWHV   
  $QDO\VLV3RSXODWLRQV   
  0XOWLSOH7HVWLQJD QG&RPSDULVRQV   
  $GMXVWPHQWIRU&RYDULDWHV   
  6XEJURXSV   
  3UHVHQWDWLRQ2YHU7LPH   
  $OJRULWKP&RPSXWDWLRQDQG'HIL QLWLRQRI'HULYHG9DULDEOHV   
  3URJUDPPLQJ&RQYHQWLRQV   
 6WDWLVWLFDO$QDO\VHV   CCI
CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI  3DWLHQW'LVSRVLWLRQ   
  'HPRJUDSKLFVDQG%DVHOLQ H&KDUDFWHULVWLFV   
  3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV   
  0HGLFDO+LVWRU\   
  3K\VLRWKHUDSHXWLF,QWHUYHQWLRQV   
  3URWRFRO'HYLDWLRQV   
  ([SRVXUHWR6WXG\'UXJ   
  6DIHW\$QDO\VHV   
  $GYHUVH(YHQWV   
  $GYHUVH(YHQWVRI6SHFLDO,QWHUHVW   
  $GGLWLRQDO$GYHUVH(YHQWVIRU5HYLHZ   
  &OLQLFDO/DERUDWRU\(YDOXDWLRQ   
  9LWDO6LJQVDQG2WKHU3K\VLFDO)LQGLQJV   
  (OHFWURFDUGLRJUDPVDQG(FKRFDUGLRJUDPV   
  2WKHU6DIHW\$VVHVVPHQWV   
  (IILFDF\$QDO\VHV   
  $QDO\VLVRI6HFRQGDU\(IILFDF\( QGSRLQWV0XVFOH%LRSV\%DVHG( QGSRLQWV  
  3KDUPDFRNLQHWLF$QDO\VHV   
 &KDQJHVLQ3ODQQHG$QDO\VHV   
  &KDQJHVIURP&OLQLFDO3URWR FRO3ODQQHG$QDO\VHV   
  &KDQJHVIURP3UHYLRXV6WDW LVWLFDO$QDO\VLV3ODQV   
 $SSHQGH[$EQRUPDOLWLHVRI,QWHUHVW   

 CCICCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506
$EEUHYLDWLRQ  ([SDQGHG7HUP$(DGYHUVH HYHQW
$ 8 &  $ U H D XQGHUWKHSODVPDFRQFHQWUDWLRQFXUYH
&',6&&OLQLFDO'DWD,QWHUFKD QJH6WDQGDUGV&RQVRUWLXP
& P D [  0 D [ L P X P  S O D V P D  F R Q F H Q W U D W L R Q 
& /  7 R W D O  F O H D U D Q F H 
& / 5   5 H Q D O  F O H D U D Q F H & 6 5  & O L Q L F D O  6 W X G \  5 H S R U W 
' 0 '  ' X F K H Q Q H  P X V F X O D U  G \ V W U R S K \  
H & 5 )  H O H F W U R Q L F  F D V H  U H S R U W  I R U P (&*HOHFWURFDUGLRJUDP
(&+2HFKRFDUGLRJUDPHFKRFDU GLRJUDSK\
,+&    LPPXQRIOXRUHVFHQFHKLVWRFKHPLVWU\/ / 2 4  / R Z H U  / LPLWRI4XDQWLWDWLRQ
/ 9 ( )  O H I W  Y H Q W U L F X O D U  H M H F W L RQIUDFWLRQ
0HG'5$   0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
 
 
057PHDQUHVLGHQFHWLPH
 
3.    SKDUPDFRNLQHWLFV
 
373UHIHUUHGWHUP
4 7 F )  4 7  L Q W H U Y D O  F R U U H F W H G  E \  W K H  ) U L G H U L F L D  & R U U H F W L R Q  ) R U P XOD
   
6$(6HULRXVDGYHUVHHYHQ W
6 $ 3  6 W D W L V W L F D O  $ Q D O \ V L V  3 O D Q  
6 0 4  V W D Q G D U G  0 H G ' 5 $  T X H U L H V 62&6\VWHPRUJDQFODVV
W √≤  ( OLPLQDWLRQKDOIOLIH
7 ( $ (  7 U H D W P H Q W  H P H U J H Q W  D G Y H U V H  H Y H Q W CCI
CCI
CCI
CCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 6 of 39 Tmax    Time to maximum plasma concentration  
Vss    Apparent volume of distribution at steady state 
WHO Drug    World Health Organization Drug Dictionary  

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 7 of 39 1. INTRODUCTION 
The purpose of this statistical analysis plan (SAP) is to provide a detailed description of 
the statistical methods and procedures that will be used to analyze and report results for   Study 4658-203, titled ‚ÄúAn Open-Label, Multi- Center Study to Evaluate the Safety, 
Efficacy and Tolerability of Eteplirsen in Early -Stage Duchenne Muscular Dystrophy‚Äù.  
 This SAP has been prepared based on Protocol Amendment 2, dated 08 June 2017.    

6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI678'<2%-(&7,9(6
3ULPDU\2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKLVVWXG \LVWRHYDOXDWHWKHVDIHW\D QGWROHUDELOLW\RIHWHSOLUVHQ
LQSDWLHQWVZLWK'XFKH QQHPXVFXODUG\VWURSK\'0'EHWZHHQDQ G\HDUVRIDJHZKR
DUHDPHQDEOHWRH[RQVNLSSLQJ
6HFRQGDU\2EMHFWLYHV
7KHVHFRQGDU\REMHFWLYHLVWRHYD OXDWHWKHHIIHFWRIHWHSOLUVHQ RQG\VWURSKLQH[SUHVVLRQDV
PHDVXUHGE\G\VWURSKLQTXDQWLI LFDWLRQE\:HVWHUQEORWDQGG\VWU RSKLQLQWHQVLW\OHYHOV
GHWHUPLQHGE\LPPXQRIOXRUHVFHQFH RQWUHDWPHQWDVFRPSDUHGZLWK SUHWUHDWPHQW
ELRSVLHGVNHOHWDOPXVFOHWLVVXH
 


3KDUPDFRNLQHWLF2EMHFWLYHV
7KHSKDUPDFRNLQHWLF3. REMHFWLYHLVWRHYDOXDWHWKHSKDUPDFRN LQHWLFSURILOHRI
HWHSOLUVHQLQWKLVDJHJURXSCCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI678'<'(6&5,37,21
6WXG\2YHUYLHZ
7KLVLVDQRSHQODEHO PXOWLFHQWHUVWXG\WRH[SORUHWKHVDIHW\ DQGWROHUDELOLW\RI
HWHSOLUVHQLQSDWLHQWVWR\HDUV RIDJHZLWKJHQRW\SLFDOO\F RQILUPHG'0'ZLWKJHQHWLF
PXWDWLRQVDPHQDEOHWRWUHD WPHQWE\H[RQVNLSSLQJ$QXQWUHDW HGJURXS'0'
SDWLHQWVQRWDPHQDEOHWRH[RQV NLSSLQJZLOOEHHQUROOHGWR IXUWKHUHYDOXDWHWKHQDWXUDO
KLVWRU\RI'0'LQWKLVSDWLHQWSRSXODWLRQ
3DWLHQWVZLOOEHH YDOXDWHGIRULQFOXVLRQGXU LQJD6FUHHQLQJ%DV HOLQHSHULRGRIXSWR
ZHHNV(OLJLEOHSDWLHQWVIRUWK HHWHSOLUVHQWUHDWHGJURXSZLOO UHFHLYHRQFHZHHNO\,9
LQIXVLRQVRIPJNJHWHSOLU VHQIRUXSWRZHHNV$QH[WHQVL RQSHULRGPD\EH
FRQVLGHUHGSULRUWRW KHHQGRIWKHZHHNSO DQQHGGRVLQJSHULR G(OLJLEOHSDWLHQWVIRU
WKHXQWUHDWHGJURXSHJ GHOHWLRQVRIH [RQVRUZL OOQRWUHFHLYHWUHDWPHQWRI
HWHSOLUVHQ8QWUHDWHGSDWLHQWVZ LOOXQGHUJRVHOHFWVDIHW\IXQF WLRQDODQGODERUDWRU\
DVVHVVPHQWVEXWZLOOQRWSURYLGHEO RRGVDPSOHVIRU3.GHWHUPLQD WLRQRUXQGHUJRPXVFOH
ELRSV\SURFHGXUHV
6DIHW\ZLOOEHDVVHVVH GWKURXJKWKHFROOHFWLRQRIDGYHUVHHYHQW V$(VVHULRXV$(V
6$(VODERUDWRU\WHVWVHOHFWUR FDUGLRJUDPV(&*VHFKRFDUGLR JUDPV(&+2VYLWDO
VLJQVDQGSK\VLFDOH[DPLQDWLRQVWKURXJKRXWWKHVWXG\
8SRQTXDOLILFDWLRQIRUWKHVWXG\S DWLHQWVHQUROOHGLQWRWKHHW HSOLUVHQWUHD WHGJURXSZLOO
XQGHUJRWKHEDVHOLQHDVVHVVPHQWVL QFOXGLQJDPXVFOHELRSV\ZKL FKPD\RFFXUDWD
GLIIHUHQWVWXG\VLWHGHQRWHGDV WKHVXUJLFDOXQLWWKDQZKHUH SDWLHQWVZLOOXQGHUJR
LQIXVLRQVDQGVWXG\DVVHVVPHQWV GHQRWHGDVWKHLQIXVLRQVLWH (WHSOLUVHQWU HDWHGSDWLHQWV
ZLOOEHUDQGRPL]HGW RXQGHUJRDVHFRQGPXVFOHELRSV\VFKHGXOHG DW:HHNRU:HHN
 


%ORRGVDPSOHVIRUSRSXODWLRQ3.HV WLPDWLRQZLOOEHFROOHFWHGIU RPDOOHWHSOLUVHQWUHDWHG
SDWLHQWV%ORRGVDPSOHVIRUVHU LDO3.HVWLPDWL RQZLOOEHFROOHF WHGDWVHOHFWVLWHV
)ROORZLQJWKHHQGRIWKHZHHNO\L QIXVLRQVSDWLHQWVZLOOEHUHT XLUHGWRUHWXUQWRWKHVWXG\
VLWHIRU(QGRI6WXG\VDIHW\HYDOXDWLRQV
5DQGRPL]DWLRQRI0XVFO H%LRSV\6FKHGXOH
$OOHWHSOLUVHQWUHDWH GSDWLHQWVZLOOKDYHDPXVFOHELRSV\SHUIR UPHGDW%DVHOLQH
$GGLWLRQDOO\HWHSOLU VHQWUHDWHGSDWLHQWV ZLOOEHUDQGRPO\DVVL JQHGWKURXJKLQWHUDFWLYH
UHVSRQVHWHFKQRORJ\,57WRD VHFRQGPXVFOHELRSV\WREHSHUIR UPHGDW:HHNRU
8QWUHDWHGSDWLHQWVZLOOQRWKDYH PXVFOHELRSVLHVSHUIRUPHG
%OLQGLQJ
7KHHYDOXDWLRQRIWKHTXDQWLILFD WLRQRIWKHG\VWURSKLQSURWHLQ IURPPXVFOHELRSVLHVZLOO
EHSHUIRUPHGE\SHUVRQQHOEOL QGHGWRWKHWLPHSRL QWRIWKHSDWL HQW
VPXVFOHELRSV\LH
SUHDQGRQWUHDWPHQWCCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI,QRUGHUWRDYRLGELDVFOLQLFDOH YDOXDWRUVSHUIRUPLQJIXQFWLRQ DODVVHVVPHQWVHJ 
ZLOOEHEOLQGHGWRVWXG\WUH DWPHQWZLOOQRWEHLQYROYHGLQW KHFOLQLFDO
FDUHRISDWLHQWVDQGZLOOQRWDFFHVVDQ\FOLQLFDORUVDIHW\UH ODWHGSDWLHQWLQIRUPDWLRQ
(YDOXDWLRQRI  
DVVHVVRUVZLOOEHEOL QGHGWRSDWLHQWLGHQWLW\DQGVWXG\WUHDWP HQW
6WXG\(QGSRLQWVDQG2WKHU9DULDEOHV
6DIHW\(QGSRLQWV
7KHIROORZLQJHQGSRLQWVZLOOEH DFFHVVHGIRUDOO SDWLHQWVLQWK HVWXG\
x,QFLGHQFHRIDGYHUVHHYHQWV
x,QFLGHQFHRIFOLQLFDO ODERUDWRU\DEQRUPDOLWLHVKHPDWRORJ\FKH PLVWU\
FRDJXODWLRQXULQDO\VLV
x,QFLGHQFHRIDEQRUPD OLWLHVLQYLWDOVLJQVDQGSK\VLFDOH[DPLQDW LRQV
x,QFLGHQFHRIDEQRUPD OLWLHVRQ(&*VDQG(&+2V
6HFRQGDU\(QGSRLQWV
&KDQJHIURP%DVHOLQHWR:HHNVDQGIRUWKHIROORZLQJ
x'\VWURSKLQSURWHLQOHYHOVTXDQWLI LHGE\:HVWHUQEORWHWHSOLUVH QWUHDWHGSDWLHQWV
RQO\
x'\VWURSKLQLQWHQVLW\DVGHWHU PLQHGE\LPPXQRIOXRUHVFHQFHKLVWRF KHPLVWU\,+&
HWHSOLUVHQWUHDWH GSDWLHQWVRQO\
 
 
 

 

 

 
 

 
CCICCI
CCI
CCICCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 11 of 39 3.2.4 Pharmacokinetic Endpoints  
The following PK parameters will be determined, as appropriate for eteplirsen -treated 
patients only: 
‚Ä¢ Maximum plasma concentration (Cmax)  
‚Ä¢ Time to maximum plasma concentration (tmax)  
‚Ä¢ Area under the plasma concentration -curve (AUC)  
‚Ä¢ Apparent volume of distribution at steady state (Vss) 
‚Ä¢ Elimination half -life (t¬Ω) 
‚Ä¢ Total clearance (CL)  
‚Ä¢ Mean residence time (MRT)  
‚Ä¢ Renal clearance (CL R) 
3.3. Sample Size and Power  
 
Sample size for this study is based upon qualitative considerations; no formal sample size calculations will be performed. Up to 40 patients will be included in this study: approximately  20 patients in the eteplirsen- treated group  (those amenable to exon 51 
skipping) and up to 20 in the untreated control group (those not amenable to exon 51 skipping). 
3.4. 
Planned Analyses 
3.4.1  Periodic Safety Data Reviews 
Periodic safety analyses will be performed for Investigator's Brochure (IB) update, and 
regulatory submissions (Development Safety Update Report [DSURs]) as necessary. 
These periodic safety analyses will continue to be performed approximately every 12 months during this study.   
3.4.2 Final Analysis  
A final analysis of safety and efficacy will be conducted once the last patient completes 
or discontinues the entire study and the resulting database is cleaned, quality assured, and locked. All statistical analyses will be performed by or under the supervision of the Sponsor. 
All available data will be included in data listings and tabulations.  
Because the untreated control group had not been able to enroll the planned number (20) 
of patients, had a high dropout rate, and resulted in a very small sample size , an external 
control dataset  may be identified and used to evaluate the effect of eteplirsen treatment. 
The statistical methods for the identification and use of the external control dataset may 
be presented in a separate SAP if deemed appropriate. The results from analysis of 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 12 of 39 eteplirsen treated patients as compared to an external control if performed will not be 
included in the Clinical Study Report ( CSR), but may be reported in a standalone report. 

6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI*(1(5$/67$7,67,&$/0(7+2'6$1'
&219(17,216
*HQHUDO0HWKRGV
6XPPDU\VWDWLVWLFVZ LOOEHSUHVHQWHGE\WUHDWPHQWJURXSXQOHVV VWDWHGRWKHUZLVH
7UHDWPHQWJURXSUHIHUVWRSDWLHQW VUHFHLYLQJHWHSOLUVHQDQGSDW LHQWVLQWKHXQWUHDWHG
JURXS
)RUFRQWLQXRXVYDULDEOHVGHVFUL SWLYHVWDWLVWLFVZLOOLQFOXGHW KHQXPEHURISD WLHQWVZLWK
GDWDWREHVXPPDUL]HGQPHD QVWDQGDUGGHYLDWLRQPHGLDQPL QLPXPDQGPD[LPXP
)RUFDWHJRULFDOTXDOLWDWLYHYDULDEOHVGHVFULSWLYHVWDWLVWLFVZ LOOLQFOXGHIUHTXHQF\FRXQWV
DQGSHUFHQWDJHV7KHWRWDOQXPEHU RISDWLHQWVLQD WUHDWPHQWJU RXSZLOOEHXVHGDVWKH
GHQRPLQDWRUIRUSHUFHQWDJHFDO FXODWLRQVXQOHVVVWDWHGRWKHUZLV H
+DQGOLQJRI0LVVLQJ'DWD
,PSXWDWLRQRI0LVVLQJ9DOXHV
















+DQGOLQJRI,QFRPSOHWH'DWHV
$OODYDLODEOHGDWDZ LOOEHLQFOXGHGLQGDWD OLVWLQJVDQGWDEXOD WLRQV
$QLQFRPSOHWHGDWHZLOORFFXUZKHQWKHH[DFWGDWHDQHYHQWRFFX UUHGRUHQGHGFDQQRWEH
REWDLQHGIRUDSDWLHQW,QFRPSOH WHGDWHVZLOOEHL PSXWHGDVGHV FULEHGEHORZ1RRWKHU
LPSXWDWLRQRIPLVVLQJGD WDZLOOEHSHUIRUPHG
x)RUDSDUWLDORUPLVVLQJPHGL FDWLRQGDWHWKHPHGLFDWLRQZLOOE HFODVVLILHGDVD
FRQFRPLWDQWPHGLFDWLRQXQOHVVWKHDYDLODEOHSDUWRIWKHGDWHLQ GLFDWHVLWLV
LPSRVVLEOHIRUWKHGUXJWREHF RQFRPLWDQW)RUH[DPSOHLIRQO\ WKH\HDUIRUWKHCCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 14 of 39 stop date is availa ble and the year is prior to the year of dosing, the medication 
will be classified as a prior medication.  
‚Ä¢ For a partial AE onset date, the event will be classified as treatment emergent if 
the month and/or year of the onset date are on or after the initiation of eteplirsen for eteplirsen treated patients or after Day 1 for untreated patients  and within 28 
days of the last dose of eteplirsen  for eteplirsen treated patients or within a day  
after last visit for untreated patients, or if the month and/or year of the onset date 
are on or after the date of the qualifying visit for untreated patients. All AEs with a missing AE onset date will be classified as treatment emergent.  
‚Ä¢ For the purpose of calculating the time since DMD diagnosis or duration of prior 
corticosteroid use, if the date of DMD diagnosis or the start date of corticosteroid 
use has a missing day but known month and year, then the 15th of the month will be used in the calculation. If the date has a missing day and month and only the year is kn own, December 31st of the recorded year will be used in the calculation . 
 In all cases, the original missing or incomplete dates will be presented in the data listings.  
4.3. 
Analysis Populations  
There will be 3 analysis populations with the definitions below for analyzing safety data, 
efficacy data, biopsy data and pharmacokinetics, as appropriate. 
‚Ä¢ Full Set: Full set includes all patients who are enrolled in the eteplirsen group and 
receive at least 1 dose of eteplirsen  as well as all patients who are enrolled in the 
untreated group who have at least 1 assessment post-enrollment assessment . Full 
Set will be used for summarizing safety and efficacy data.  
‚Ä¢ Muscle Biopsy Set : This set includes all patients who receive at lea st one dose of 
eteplirsen and who have data from both Baseline (pre-treatment) and Week 48 or Week 96 (on- treatment) muscle biopsy samples.    
‚Ä¢ Pharmacokinetic Set: All patients who receive at least one dose of eteplirsen and 
for whom there are adequate PK s amples with which to estimate PK parameters. 
The PK Set will be further described in a separate PK SAP.  
4.4. 
Multiple Testing and Comparisons  
No adjustment will be made for the testing of multiple endpoints.  
4.5. Adjustment for Covariates 
Not applicable.  
4.6. Subgroups  
Due to small sample size, no subgroups will be identified for this study.  

6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI3UHVHQWDWLRQ2YHU7LPH
)RUHQGSRLQWVWKDWDUHFROOHFWH GVHULDOO\RYHUWLPHDVVHVVPHQW VWHVWYDOXHVZLOOEH
DVVLJQHGWRDVSHFLILFWLPHSRLQWHJVWXG\ZHHNEDVHGXSRQ WKHHOHFWURQLFFDVHUHSRUW
IRUPH&5)SDJHRQZKLFKWKHDVV HVVPHQWVWHVWYDOXHVZHUHUHSR UWHG
)RUDQHIILFDF\HQGSRLQWDQXQVFKHGXOHGHDUO\WHUPLQDWLRQDVVH VVPHQWPD\EHXVHGLQ
WKHVXPPDU\E\WLPHSRLQWLIWKHXQV FKHGXOHGDVVHVVPHQWZDVZLWK LQZHHNVRID
PLVVLQJVFKHGXOHGDVVHVVPHQW,I XQVFKHGXOHGDVVHVVPHQWVDUHFR OOHFWHGZLWKPXOWLSOH
GDWHVRUWLPHVZLWKLQD JLYHQYLVLWWKHUHVXOWFORVHVWWRWKH VFKHGXOHGYLVLW GDWHZLOOEH
XVHGIRUVXPPDU\SUHVHQWDWLRQV ,IPHDVXUHPHQWVKDYHWKHVDP HGLVWDQFHWRWKH
H[SHFWHGGDWHWKHHDUOLHUD VVHVVPHQWYDOXHZLOOEHXVHG
)RUVDIHW\HQGSRLQWVXQVFKHGXOH GDVVHVVPHQWVZLOOQRWEHLQFOX GHGLQWKHVXPPDU\E\
WLPHSRLQW
$OJRULWKP&RPSXWDWLRQDQG'HIL QLWLRQRI'HULYHG9DULDEOHV
'D\
)RUHWHSOLUVHQWUHDWHGSDWLHQWV 'D\ZLOOEHGHILQHGDVWKHG DWHRIWKHILUVWHWHSOLUVHQ
DGPLQLVWUDWLRQ)RUXQWUHDWHGSD WLHQWV'D\ZLOOEHGHILQHGD VWKHGDWHRIWKHODVW
6FUHHQLQJ:HHNDVVHVVPHQW
6WXG\'D\6WXG\GD\ZLOOEHGHILQHGDV(YHQ W'DWH¬±'D\LI(YHQW' DWHLVRQRUDIWHU'D\
RWKHUZLVHDV(YHQW'DWH¬±' D\LI(YHQW'DWHSUHFHGHV'D\ 
'XUDWLRQRQ6WXG\'XUDWLRQRQVWXG\ZLOOEHFDOFXOD WHGDVWKHGXUDWLRQLQZHHNVI URP'D\WRWKHGDWHRI
VWXG\FRPSOHWLRQGLVFRQWLQXDWL RQDVUHFRUGHGRQWKH(1'2)678' <H&5)LI
FRPSOHWHGRUWKHGDW HRIWKHODVWVWXG\DVVHVVPHQWRUSURFHGXU H7KHGXUDWLRQLQZHHNV
FDOFXODWHGDERYHZLOOWKHQEHFDW HJRUL]HGWRRQHRIWKHIROORZL QJLQWHUYDOVWR
WRWR¬ï
'XUDWLRQRI7UHDWPHQW)RUWUHDWHGSDWLHQWV GXUDWLRQRIHWHSOLUVH QWUHDWPHQWZLOOEH FDOFXODWHGDVWKHGXUDWLRQLQ
ZHHNVIURPWKHGDWHRIILUVWGRV HRIHWHSOLUVH QWRWKHGDWHRI WKHODVWHWHSOLUVHQ
DGPLQLVWUDWLRQDVUHFRUGHGRQWKH 678'<'58*$'0,1,675$7,21H&5 )SOXV
GD\VRUZHHNLH/DVWGRV HGDWHILUVW GRVHGDWH 7KHGXUDWLRQLQZHHNV
FDOFXODWHGDERYHZLOOWKHQEHFDW HJRUL]HGWRRQHRIWKHIROORZL QJLQWHUYDOVWR
WRDQG¬ï
%DVHOLQH
)RUWUHDWHGSDWLHQWV EDVHOLQHZLOOEHGHIL QHGDVWKHODVWYDOX HSULRUWRWKHILUVWGRVHRI
HWHSOLUVHQDGPLQLVWUDWLRQ)RUXQW UHDWHGSDWLHQWVEDVHOLQHZLO OEHGHILQHGDVWKHODVWYDOXH
RQRUEHIRUHWKH'D\GDWH

CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI
















 
 
3ODQQHG'RVHDQG2YHUGRVH
7KHERG\ZHLJKWEDVHGSODQQH GGRVHZDVFDOFXODWHGEDVHGRQPRVW UHFHQWZHLJKWRI
SUHYLRXVYLVLWV:KHQFDOFXODWLQ JWKHSODQQHGGRVHWKHERG\ZH LJKWLVURXQGHGWRVLQJOH
GHFLPDOXVLQJFRQYHQ WLRQDOURXQGLQJUXOHV:KLOHLQSUHSDULQJD FWXDOGRVHDQ
XQFRQYHQWLRQDOUXOHLVDSSOLHGIRU FDOFXODWLQJWKHYROXPHRIWK HFRQFHQWUDWHGGUXJ
PJPOLQPLOOLOLWHU$Q\YROXPH QXPEHURUDE RYHLVURXQGHG XSHJPOLV
URXQGHGXSWRPODQGDQ\YROXPH QXPEHUEHORZLVURXQGHG GRZQHJPO
LVURXQGXSWRPO7KHRYHUGRVHLV GHILQHGDVDQ\DFWXDOGR VH!DERYHWKH
SODQQHGERG\ZHLJKWEDVHGGRVH 
7UHDWPHQWHPHUJHQW$GYHUVH(YHQW7($(
)RUWUHDWHGSDWLHQWVDQ$(ZLOO EHFRQVLGHUHGWUHDWPHQWHPHUJH QWLILWVWDUWVLQWKHWLPH
SHULRGVWDUWLQJZLWKWKHLQLWLD WLRQRIWKHILUVW GRVHRIHWHSOL UVHQDQGHQGLQJGD\VDIWHU
WKHODVWGRVHRIHWHS OLUVHQ)RUXQWUHDWH GSDWLHQWVDQ$(ZLOO EHFRQVLGHUHGWUHDWPHQW
HPHUJHQWLILWVWDUWVRQRUDIWHUWKH'D\GDWH
7UHDWPHQWUHODWHG$GYHUVH(YHQW
$WUHDWPHQWUHODWHG$(LVDQ\$ (UHSRUWHGRQWKH$'9(56((9(176 H&5)WKDWLV
PDUNHGDVGHILQLWHO\UHODWH GRUSUREDEO\SRVVLEO\UHODWHGWRV WXG\GUXJ
7UHDWPHQW(PHUJHQW/DERUDWRU\$EQRUPDOLW\CCI
CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI)RUWUHDWHGSDWLHQWVDWUHDWPHQW HPHUJHQWODERUDWRU\DEQRUPDOL W\ZLOOEHGHILQHGDVDQ\
ODERUDWRU\DEQRUPDOLW\RFFXUULQJRUZRUVHQLQJDIWHUWKHLQLWLDW LRQRIHWHSOLUVHQGRVLQJ
DQGZLWKLQGD\VRIWKHODVWGRVH RIHWHSOLUVHQ)RUXQWUHDWH GSDWLHQWVDWUHDWPHQW
HPHUJHQWODERUDWRU\DEQRUPDOLW\ ZLOOEHGHILQHGDVDQ\ODERUDWR U\DEQRUPDOLW\RFFXUULQJ
RUZRUVHQLQJRQRUDIWHUWKH: HHN6FUHHQLQJDVVHVVPHQW
3ULRU0HGLFDWLRQ$SULRUPHGLFDWLRQZLOOEHDQ\P HGLFDWLRQWDNH QDQGFRPSOHWHGS ULRUWRWKHILUVWGRVHRI
HWHSOLUVHQIRUWUHDWHGSDWLHQW VRURQRUEHIRUHWKH'D\GDWH IRUXQWUHDWHGSDWLHQWV
&RQFRPLWDQW0HGLFDWLRQ
$FRQFRPLWDQWPHGLFDWLRQZLOOEHDQ\PHGLFDWLRQWKDWLVWDNHQL QWKHWLPHSHULRGVWDUWLQJ
ZLWKWKHLQLWLDWLRQRIW KHILUVWGRVHRIHWH SOLUVHQDQGHQGLQJ GD\VDIWHUWKHODVWGRVHRI
HWHSOLUVHQIRUWUHDWHGSDWLHQW VRURQRUDIWHUWKH'D\GDWHI RUXQWUHDWHGSDWLHQWV

























CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI

 
 
 
 
 
 
3URJUDPPLQJ&RQYHQWLRQV
7KLVVHFWLRQGHWDLOVJH QHUDOFRQYHQWLRQVW REHXVHGIRUWKHSUR GXFWLRQRIWDEOHVILJXUHV
DQGOLVWLQJV'HSDUWXUHVIURPW KHVHJHQHUDOFRQYHQWLRQVZLOOEH VSHFLILHGLQDSSURSULDWH
VHFWLRQV
x)RUFRQWLQXRXVRUTXDQWLWDWLYHYDUL DEOHVPHDQDQGPHGLDQYDOXH VZLOOEH
IRUPDWWHGWRPRUHGHFLPDOSODFH WKDQWKHPHDVXUHGYDOXHRQWK HH&5)
6WDQGDUGGHYLDWLRQD QGVWDQGDUGHUURUYDOX HVZLOOEHIRUPDWWHG WRPRUHGHFLPDO
SODFHVWKDQWKHPHDVXUHGYDOX HRQWKHH&5)0LQ LPXPDQGPD[LPX PYDOXHV
ZLOOEHSUHVHQWHGZLWKWKHVDPH QXPEHURIGHFLPDOSODFHVDVWKH PHDVXUHGYDOXH
RQWKHH&5)3HUFHQWDJHVZLOOEH SUHVHQWHGZLWKGHFLPDOSODF H
x)RUFDWHJRULFDOYDULDEOHVWKHQXPEHUDQGSHUFHQWDJHRIDFDWHJ RU\ZLOOEH
SUHVHQWHGLQWKHIRUP;;<<Z KHUHWKHSHUFHQWDJHLV<<
x3HUFHQWDJHVRISDWLHQWVZLWKODERUDWRU\WR[LFLWLHVZLOOEHEDVH GRQQRQPLVVLQJ
YDOXHVXQOHVVVWDWHGRWKHUZLVH
x6WXG\'D\ZLOODSSHDULQWKHGDWDOLVWLQJVDVDSSURSULDWH
x'DWHYDULDEOHVZLOOEH IRUPDWWHGDV''000<< <<IRUSUHVHQWDWLRQ 
x6$6¬ì9HUVLRQRUKLJKHUZLOOEHWKHV WDWLVWLFDOVRIWZDUHSDFNDJH XVHGIRUDOO
DQDO\VHVXQOHVVRWKHUZLVHVSHFLILHG
x7KH&OLQLFDO'DWD,QWHUFKDQJH6WD QGDUGV&RQVRUWLXP&',6&$QDO \VLV'DWD
0RGHO,PSOHPHQWDWLRQ*XLGH$'D0, *9IRUSUHSDULQJGDWDVHW VZLOOEH
XVHGIRUWKLVVWXG\
x7KH&',6&6WXG\'DWD7DEXODWL RQ0RGHO,PSOHPHQWDWLRQ*XLGH6'7 0,*
9IRUSUHSDULQJGDWDVHWVZ LOOEHXVHGIRUWKLVVWXG\
x7DEOHVILJXUHVDQGOLVWLQJVZ LOOEHSUHVHQWHGLQODQGVFDSHRU LHQWDWLRQ
x/LVWLQJVZLOOEHVRUWHGE\WUHD WPHQWSDWLHQWDQ GWKHQDVVHVVPH QWRUHYHQWVWDUW
GDWHXQOHVVRWKHUZ LVHVSHFLILHG
CCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 19 of 39 5. STATISTICAL ANALYSES  
5.1. Patient Disposition  
 
The number of patients enrolled, the number in the safety population, the number 
randomized to muscle biopsy, the duration of the study (weeks) [both continuous and 
categorical interval summaries], the number and percentage of patients completing the study through Week 96 (i.e., completers), and the number and percentage of patients prematurely discontinuing before Week 96 will be summarized. Reasons for premature 
discontinuation will also be summarized. All analyses will be performed by treatment group.  Patient eligibility will be presented in a listing.  
5.2. 
Demographics and Baseline Characteristi cs 
Demographic characteristics including age (years), race, ethnicity, and baseline 
characteristics including height (cm), weight (kg), body mass index (BMI; kg/m2), time 
since DMD diagnosis (months) to Baseline, corticosteroid type (Deflazacort or 
Prednisone), corticosteroid frequency (continuous versus intermittent), mutation type(s), and duration of prior corticosteroid treatment (months) to Day 1 will be summarized by 
treatment group. Demographic data and baseline characteristics will also be presented in 
data listings.  
5.3. 
Prior and Concomitant Medications  
Concomitant medications will be coded by preferred term (PT) using the most recent 
World Health Organization (WHO) Drug Dictionary (WHODRUG, 01DEC2013). The 
number and percentage of patients in the safety population taking concomitant 
medications will be tabulated by Anatomical Therapeutic Chemical (ATC) classification , 
pharmacological subgroup, and WHO drug PT  by treatment group . At each level of 
summarization, a patient is counted once if he/she reported 1 or more medications at that level. 
All prior medications and concomitant medication will be presented in data listings.  
5.4. 
Medical History  
 Medical history data for the safety set will be presented in data listings.  
5.5. Physiotherapeutic Interventions  
A listing of all physiotherapeutic interventions will be provided.  
5.6. Protocol Deviations 
A listing of major protocol deviations will be provided. The protocol deviations will be identified based on a review of the study data prior to the database lock and will include the nature of the deviation (e.g., inclusion/exclusion, prohibited therapies). 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 20 of 39 5.7. Exposure to Study Drug  
The total number of infusions received, cumulative amount of drug received (mg), total 
volume of drug administered (mL), duration on eteplirsen in 24-week intervals, and the 
continuous number of weeks on eteplirsen will be summarized for all eteplirsen- treated 
patients. Dosing information will be provided in a data listing. 
A listing of patients with overdose will be generated.  
5.8.  Safety Analyses  
 Safety analyses will be descriptive in nature. Safety analyses will include summaries of 
the following: 
‚Ä¢ The type, frequency, severity, timing, and relationship to the investigational drug product of AEs, SAEs, and discontinuations due to AEs. Adverse event s will be 
coded using the Medical Dictionary for Regulatory Activities (MedDRA 17.1 or higher) and will be reported by primary system organ class (SOC) and PT. 
‚Ä¢ Safety laboratory testing including hematology, coagulation, serum chemistry, and urinalysis 
‚Ä¢ Vital signs 
‚Ä¢ Physical examinations   
‚Ä¢ ECG and/or ECHO   
5.8.1 Adverse Events  
In general, only TEAEs will be summarized (for untreated subjects, AEs that first occur 
or worsen in severity after the study enrollment are considered treatment -emergent).  
Non-treatment -emergent adverse events will be recorded in the data listings. Unless noted 
otherwise, for all AE tables, the number and percentage of patients reporting AEs will be grouped using the MedDRA , SOC, and PT and summarized for treated patients, untreated 
patients, and overall. 
An overall summary table of adverse events will be produced and will include the 
frequency count and percentage of patients with  
o   TEAE 
o   Treatment -related TEAE  
o   Severe TEAE  
o   Treatment -Emergent SAE  
o   Treatment -Emergent Related SAE  
o   TEAE leading to discontinuation of study drug 
o   TEAE leading to death  
The number of events at each severity level (mild, moderate, severe)  will also be 
included. 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 21 of 39 Multiple occurrences of the same AE (at the PT level) in the same patient will be counted 
only once in frequency tables. If a patient experiences multiple episodes of the same 
event with  a different relationship/severity, the event with the strongest relationship or 
maximum severity to investigational drug product will be used to summarize AEs by relationship and severity. 
The following summary tables will be produced: 
‚Ä¢ TEAEs by SOC and PT  
‚Ä¢ TEAEs by SOC, PT and severity  
‚Ä¢ TEAE by PT in descending frequency  
‚Ä¢ Treatment -related TEAEs by SOC and PT  
‚Ä¢ Treatment-related TEAEs by SOC, PT, and severity 
‚Ä¢ Treatment -related TEAEs by PT  in descending frequency 
‚Ä¢ Treatment -Emergent SAEs  by SOC and PT 
‚Ä¢ Treatment -related Treatment -Emergent SAEs  by SOC and PT 
‚Ä¢ TEAEs leading to treatment discontinuation  by SOC and PT 
‚Ä¢ TEAEs leading to death  by SOC and PT 
‚Ä¢ Non-serious TEAEs by SOC and PT, displaying both number of subjects and 
number of events 
The following listings will be produced: 
‚Ä¢ All AEs 
‚Ä¢ AEs leading to treatment discontinuation  
‚Ä¢ SAEs 
5.8.2 Adverse Events of Special Interest  
Summaries of TEAEs of special interest will be summarized by SOC and PT. All 
standard MedDRA queries (SMQs based on MedDRA version 17.1) listed below will include broad and narrow terms. The AEs of special interest (AESI) are:  
‚Ä¢ Hypersensitivity (hypersensitivity SMQ)   
‚Ä¢ Renal toxicity ( acute renal failure SMQ)  
‚Ä¢ Infusion-related reaction (IRR) (AEs occurring within 24 hours of the start of any infusion [including events that occurred on the same date as an infusion where infusion start time or AE onset time was not reported]) 
For all IRRs as defined above, adjudicated IRRs will be identified by  a 
pharmacovigilance physician. All IRRs as defined above that are considered as related to study drug by investigators will be counted in the list of adjudicated IRRs. In addition, all 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 22 of 39 IRRs as defined above that meet the following criteria will be excluded from the list of 
adjudicated IRRs:  
‚Ä¢ AE was an infusion site, application site, or other local AE not associated with 
IRR  
‚Ä¢ AE had a clear alternate etiology that could be ascertained based on the 
reported event (eg, reaction to plaster, assessed as related to procedure or underlying disease by investigator) 
‚Ä¢ AE not associated with an IRR due to the nature of the event or biologically implausible (eg, fibula fractu re, chalazion)  
 A summary table will be generated and include the following: 
‚Ä¢ Number of patients with adjudicated IRRs 
‚Ä¢ Number of adjudicated IRRs 
‚Ä¢ Number of adjudicated IRRs with event start time reported  
‚Ä¢ Number of events on any day for adjudicated IRRs  
A corresponding listing will be generated for each table. Additionally, a table and listing 
corresponding to the AESIs that were related to study drug or moderate or severe will be produced. 
An overall summary of AESI events will include the total number of events, number of 
serious events, number of related events, number of not related events, number of mild 
events, number of moderate events, number of severe events, and number of events occurring on the same day as an infusion.  
5.8.3 Additional Adverse Events fo r Review  
Summaries of Additional TEAEs for review will be summarized by SOC and PT. All 
SMQs based on MedDRA Version 17.1 are listed below and will include broad and narrow terms.  
Additional AEs for review are: 
‚Ä¢ Drug-induced hepatotoxicities ( cholestasis and jaundice of hepatic origin SMQ, 
hepatic failure, fibrosis, cirrhosis, and other liver damage-related conditions SMQ, 
hepatitis, noninfectious SMQ, liver neoplasms, benign [including cysts and polyps] 
SMQ, liver malignant tumors SMQ, liver tumors of unspecified malignancy SMQ, 
liver-related investigations, signs and symptoms SMQ, liver- related coagulation and 
bleeding disturbances SMQ) 
‚Ä¢ Cardiac events (cardiomyopathy SMQ, cardiac failure SMQ, and arrhythmia related investigations, sign and symptoms SMQ) 
‚Ä¢ Thrombocytopenia (hematopoietic thrombocytopenia SMQ) 
‚Ä¢ Port-related events (embolic and thrombotic events, venous SMQ, extravasation 
events (injections, infusions, and implants) SMQ, PTs in the following High Level 
Terms (HLTs): sepsis, bacteremia, viremia and fungemia NEC (not elsewhere 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 23 of 39 classified), implant and catheter site reactions, PTs in the following HLGTs: 
endocardial disorders, and device issues. In addition, a search will be performed on 
the verbatim terms for ‚Äúport‚Äù, ‚Äúcentral venous‚Äù and ‚Äúcentral line‚Äù). Note: The port-
related events will only be identified for patients who have a port placed/inserted and 
for events that occur after the port insertion occurred. It is noted that port insertion 
may occur during treatment or prior to the start of treatment. Percentages will be calculated based on the total number of patients who have had a port inserted 
A corresponding listing will be generated for each table. Additionally, a table and listing corresponding to the additional AEs for review that were related to study drug or moderate or severe will be produced. 
An overall summary of additional AEs for review will include total number of events, 
number of serious events, number of related events, number of not related events, number of mild events, number of moderate events, number of severe events, and number of events occurring on the same day as an infusion.  
5.8.4 Clinical Laboratory Evaluation 
Clinical chemistry, hematology, coagulation, and urinalysis results will descriptively be 
summarized by treatment group and by selected time point. Baseline value, 
highest/low est postbaseline value, and final observation and the corresponding change 
from Baseline will be summarized for treated patients and untreated patients. Frequency 
tables of patients with potentially clinically significant laboratory parameter values at any  
time point will be generated. The total number of potentially clinically significant values will also be summarized. Potentially clinically significant values can be found in Appendix 1 tables 1 -3. 
A shift table will present the number and percentage of patients in each cell resulting  
from cross -tabulating the status (low, normal, and high) of the highest/lowest 
postbaseline value versus that of the baseline for each laboratory test, if applicable, by 
treatment group. If a specific test can have both a sig nificant low and high, then a shift 
table will be generated for each direction. The percentage will be based on the total number of patients in the Safety Set. 
All patient- level clinical laboratory values will be displayed in data listings.  In addition, 
values meeting the potentially clinically significant abnormalities criteria will be 
presented in data listings.  Treatment -emergent abnormalities will be indicated in the 
listing. 
5.8.5 Vital Signs and Other Physical Findings  
Vital signs, height/length, and weig ht will be summarized by treatment group and by 
selected time point. Baseline value, highest/lowest postbaseline value, and final 
observation and the corresponding change from Baseline will be summarized for treated 
patients, untreated patients. Highest/lo west value is considered as the largest absolute 
change from Baseline for systolic blood pressure, diastolic blood pressure, and 
respiratory rate, and highest value for pulse rate and temperature. The highest/lowest 
value will not be summarized for height, weight, or ulnar length. Frequency tables of patients with potentially clinically significant vital sign values will be generated. The 

6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRIWRWDOQXPEHURISRWHQWLDOO\FOLQLF DOO\VLJQLILFDQWYDOXHVZLOO DOVREHVXPPDUL]HG
3RWHQWLDOO\FOLQLFDOO\VLJQLIL FDQWYDOXHVFDQEHIRXQGLQ$SSHQ GL[7DEOH
9LWDOVLJQVZLOOEHOLVWHGIRU DOOSDWLHQWV,QDGGLWLRQYDOX HVPHHWLQJWKHSUHGHILQHG
PDUNHGO\DEQRUPDOFULWHULDZLOO EHSUHVHQWHGLQDGDWDOLVWLQJ 7UHDWPHQWHPHUJHQW
DEQRUPDOLWLHVZLOOEHL QGLFDWHG+HLJKWDQGZHLJKWZLOODOVREH OLVWHG
(OHFWURFDUGLRJUDPVDQG(FKRFDUGLRJUDPV
)RUHDFK(&*SDUDPHWHUWKH%DVHOLQHYDOXHWKHKLJKHVWORZHVW SRVWEDVHOLQHYDOXHILQDO
REVHUYDWLRQDQGWKHFRUUHVSRQGLQJ FKDQJHIURP%DVHOLQHZLOOEH VXPPDUL]HGIRUWUHDWHG
SDWLHQWVDQGXQWUHDWH GSDWLHQWV7KHKLJKHVWORZHVW(&*YDOXHL VWKHODUJHVWFKDQJHIRU
47,QWHUYDOFRUUHFWHGE\WKH)ULG HULFLD&RUUHFWLRQ)RUPXOD47F )456DQG35
LQWHUYDOVKLJKHVWYDOXHIRU47 DQGODUJHVWDEVROXWHFKDQJHIR UKHDUWUDWH)UHTXHQF\
WDEOHVRISDWLHQWVZLW KSRWHQWLDOO\FOLQLFDOO\VLJQLILFDQW(&* YDOXHVZLOODOVREH
JHQHUDWHG7KHWRWDOQXPEHURISRW HQWLDOO\FOLQLFDOO\VLJQLILFD QWYDOXHVZLOODOVREH
VXPPDUL]HG3RWHQWLDOO\FOLQLFDOO\ VLJQLILFDQWYDOXHVFDQEHIR XQGLQ$SSHQGL[7DEOH
)RUHDFK(&+2SDUDPHWHULQFOXGL QJWKHOHIWYHQWULFXODUHMHFWLR QIUDFWLRQ/9()YDOXH
%DVHOLQHYDOXHILQDOREVHUYDWL RQDQGWKHFRUUHVSRQGLQJFKDQJH IURP%DVHOLQHZLOOEH
VXPPDUL]HGIRUWUHDWHGSDWLHQW VDQGXQWUHDWHGSDWLHQWV)UHTXHQ F\WDEOHVRISUHGHILQHG
PDUNHGO\DEQRUPDO(&+2YDOXHVZ LOODOVREHJHQHUDWHG0DUNHGO\ DEQRUPDOYDOXHVFDQ
EHIRXQGLQ$SSHQGL[,7DEOH
$OOSDWLHQWOHYHOYDOXHVIRU(&* DQG(&+2YDULDEOHVZLOOEHGLV SOD\HGLQDGDWDOLVWLQJ
,QDGGLWLRQYDOXHVPHHWLQJWKHSUHGHILQHGPDUNHGO\DEQRUPDOFU LWHULDZLOOEHSUHVHQWHG
LQDGDWDOLVWLQJ7UHDWPHQWH PHUJHQWDEQRUPD OLWLHVZLOOEHLQG LFDWHG
2WKHU6DIHW\$VVHVVPHQWV
$OOSK\VLFDOH[DPLQDWL RQUHVXOWVZLOOEHOLVWHG
(IILFDF\$QDO\VHV
)RUDQ\HIILFDF\DVVHVVPHQWWKDWLVWDNHQRQFRQVHFXWLYHGD\V ZLWKLQDYLVLWLH
WKHDYHUDJHYDOXHZLOOEHXVH G,IWKHDVVHVVPHQWLVWDNHQR QO\RQRQHGD\WKHQ
WKHYDOXHRQWKDWGD\ZLOOEHXVH G$YDOXHWKDWLVPDUNHGDVL QYDOLGRQWKHH&5)ZLOOEH
FRQVLGHUHGDPLVVLQJYDOXH
$QDO\VLVRI6HFRQGDU\(IILFDF\(QG SRLQWV0XVFOH%LRSV\%DVHG
(QGSRLQWV
7KHDQDO\VHVRIG\VWURSKLQSURWHL QOHYHOVGHWHUPLQHGE\:HVWHUQ EORWDQGG\VWURSKLQ
LQWHQVLW\LQPXVFOHELRSV\WLVVXH GHWHUPLQHGE\,+&ZHUHRULJLQ DOO\GHVFULEHGLQD
VHSDUDWHPXVFOHELRSV\EDVHGHQGSRL QWV6$3ZKLFKZDVDSSURYHG RQ$XJXVW
7KHPXVFOHELRSV\6$3GHVFULEH GERWKLQWHULPDQGILQDODQDO\VHV RIELRSV\HQGSRLQWV
+RZHYHUWKHLQWHULPVWDWLVWLFDO DQDO\VLVRIPXVFOHELRSV\EDVH GHQGSRLQWVZDVQRW
SHUIRUPHG$UHYLVLRQRIWKHRULJLQ DOPXVFOHELRSV\6$3LVZDUU DQWHGGXHWRFRRUGLQDWHG
DQDO\VHVRIDOOHIILFDF\HQGSRLQW VIRUVXSSRUWLQJ&657KXVWK LV6$3GHVFULELQJ
VWDWLVWLFDOPHWKRGVIRUDQDO\VHV RIPXVFOHELRSV\HQGSRLQWVZLO OVXSHUVHGHWKHSUHYLRXVCCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRIVHSDUDWHPXVFOHELRSV\6$37KH UHVXOWVRIPXVFOHELRSV\HQGSRL QWVZLOOEHUHSRUWHG
VHSDUDWHO\DVDQDGGH QGXPUHSRUWWRWKH&65
&RUUHODWLRQDPRQJGLIIHUHQWW\SHV RIG\VWURSKLQUHODWHGHQGSRLQ WVOLVWHGERWKLQWKH
VHFRQGDU\HIILFDF\HQGSRLQWVDQG PD\EHJUDSKLFDOO\
GLVSOD\HGXVLQJVFDWWHUSORW7 KH6SHDUPDQ¬∂VUDQNFRUUHODWLRQF RHIILFLHQWVZLOOEH
FDOFXODWHGLIDSSURSULDWH7KH HIIHFWRIERG\ZHLJKWDQGWUHDWP HQWGXUDWLRQRQWKH
G\VWURSKLQUHODWHGHQGSRLQWVZLOO DOVREHJUDSKLFDOO\GLVSOD\HG XVLQJVFDWWHUSORWRU
KLVWRJUDPLIGHHP HGDSSURSULDWH
4XDQWLW\RI'\VWURSKLQ3URWHLQ ([SUHVVLRQDV 0HDVXUHGE\:HVWHU Q%ORW
)RUHDFKWLPHSRLQW%DVHOLQ H:HHNRU:HHNEORFNVRI WLVVXHVZLOOEHDQDO\]HG
E\:HVWHUQEORWHDFKZLWKWZRU HSOLFDWHVRIJHOVWRGHWHUPLQH WKHG\VWURSKLQOHYHO
QRUPDO7KHEORFNDYHUDJHYDOXH IURPWZRUHSOLFDWHJHOVZLOOE HFRPSXWHG7KHRYHUDOO
DYHUDJHLVFDOFXODWHGDVWKHP HDQRIWKHEORFNDYHUDJHYDOXHV 7KHRYHUDOODYHUDJHYDOXHV
ZLOOEHXVHGIRUDOODQDO\VHV, QWKHFDVHRIRQO\DYDLODEOH JHOIRUDEORFNWKHQWKDW
YDOXHZLOOEHXVHGDVWKH EORFNDYHUDJHYDOXH
)RUWKHFDOFXODWLRQRIDYHUDJHD VVD\YDOXHLIWKHUHDUHDVVD\ UHVXOWVRXWVLGHRIWKHOLPLWV
RITXDQWLILFDWLRQGLIIHUHQWLP SXWDWLRQPHWKRGVZLOOEHXVHG 7DEOH9DOXHVOHVVWKDQ
WKHORZHUOLPLWRITXDQWLILFDWL RQ//24ZLOOEHLPSXWHGXVLQJ RQHRIPHWKRGVDVDV
OHYHOLPPHGLDWHO\EHORZWKH //24DQGDVWKHDFWXDOPHDV XUHGYDOXH2IWKHP
WKHPDLQDQDO\VLVZ LOOEHEDVHGRQWKHDFWXD OPHDVXUHGYDOXH $QDO\VHVEDVHGRQRWKHU
LPSXWDWLRQPHWKRGVZLOOEHFRQVLGHUHGVHQVLWLYLW\DQDO\VHV
7DEOH,PSXWDWLRQ0HWKRGIRU9DOXHV%HORZWKH/LPLWVIRU:HVW HUQEORW
,PSXWDWLRQ
W\SH7UHDW
YDOXH //24DV$QDO\VLVW\SH
 $VPHDVXUHG 0DLQDQDO\VLV
  6HQVLWLYLW\DQDO\VLV
  6HQVLWLYLW\DQDO\VLV

'\VWURSKLQOHYHOQRUPDOGHWH UPLQHGE\:HVWHUQEORWZLOOEH VXPPDUL]HGIRUEDVHOLQH
DQGHDFKRIWKHRQWUHDWPHQW WLPHSRLQWV:HHNDQG,QDG GLWLRQFKDQJHLQ
G\VWURSKLQIURPEDVHOLQHDQGWKH IROGFKDQJHIURPEDVHOLQHWRH DFKRQWUHDWPHQW
WLPHSRLQWVZLOOEHVXPPDUL]HG)RO GFKDQJHZLOOEHFDOFXODWHGL QWZRZD\V
FDOFXODWHGIRUHDFKLQGLYLGXDO DVSRVWEDVHOLQHYDOXHEDVHOLQH YDOXHDQGVXPPDUL]HG
XVLQJGHVFULSWLYHVWDWLVWLFV FDOFXODWHGDVWKHUDWLRRIWK HWUHDWPHQWPHDQYDOXHSRVW
EDVHOLQHWUHDWPHQWPHDQYDOXHDWEDVHOLQH
$RQHVDPSOHSHUPXWDWLRQWHVWZ LOOEHXVHGWRWHVWWKHQXOOK\S RWKHVLVWKDWWKHPHDQ
FKDQJHIURP%DVHOLQHLQG\VWURSKLQOHYHOLV,QDGGLWLRQDW WKHILQDODQDO\VLVDWZRCCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRIVDPSOHSHUPXWDWLRQWHVWZLOOEH XVHGWRWHVWWKHQXOOK\SRWKHVL VWKDWWKHPHDQFKDQJH
IURP%DVHOLQHWR:HHNLVWKHVD PHDVWKHPHDQFKDQJHIURP%D VHOLQHWR:HHN






 


 
 
&KDQJHIURP%DVHOLQHWR:HHND QG:HHNLQ'\VWURSKLQ,QWHQ VLW\
DV'HWHUPLQHGE\,PPXQRKL VWRFKHPLVWU\,+&
'\VWURSKLQLQWHQVLW\OHYHOGHWH UPLQHGE\,+&ZLOOEHEDVHGRQW KHDYHUDJHYDOXHIRUHDFK
WLPHSRLQW%DVHOLQH:HHNRU: HHN,WZLOOEHVXPPDUL]H GGHVFULSWLYHO\IRU
EDVHOLQHDQGHDFKRIWKHRQW UHDWPHQWWLPHSRL QWV:HHNDQG ,QDGGLWLRQFKDQJH
IURP%DVHOLQHDQGIROGFKDQJHIUR P%DVHOLQHZLOOEHVXPPDUL]HG GHVFULSWLYHO\)ROG
FKDQJHZLOOEHFDOFXODWHGLQWZ RZD\VFDOFXODWHGIRUHDFK LQGLYLGXDODVSRVWEDVHOLQH
YDOXHEDVHOLQHYDOXHDQGVXPPDUL ]HGXVLQJGHVFULSWLYHVWDWLVWL FVFDOFXODWHGDVWKH
UDWLRRIWKHWUHDWPHQW PHDQYDOXHSRVWEDVH OLQHWUHDWPHQWPHDQ YDOXHDWEDVHOLQH$RQH
VDPSOHSHUPXWDWLRQWHVWZLOOEH XVHGWRWHVWWKHQXOOK\SRWKHVL VWKDWWKHPHDQFKDQJH
IURP%DVHOLQHLV,QDGGLWLRQDWWKHILQDODQDO\VLVDWZR VDPSOHSHUPXWDWLRQWHVWZLOO
EHXVHGWRWHVWWKHQXOOK\SRWKHVL VWKDWWKHPHDQFKDQJHIURP% DVHOLQHWR:HHNLVWKH
VDPHDVWKHPHDQFKDQJHIU RP%DVHOLQHWR:HHN

$SDWLHQWOHYHOOLVWLQJZLOOEHSURYLGHG
 



 



CCI
CCI
CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI




 












 















3KDUPDFRNLQHWLF$QDO\VHV

)RUHWHSOLUVHQWUHDWHGSDWLHQWVL QGLYLGXDOSODVPDOHYHOVRIHW HSOLUVHQZLOOEHOLVWHGZLWK
WKHFRUUHVSRQGLQJWLPHUHODWHGW RHWHSOLUVHQDG PLQLVWUDWLRQDQG VXPPDU\VWDWLVWLFVZLOOEH
JHQHUDWHGE\SHUSURWRF ROWLPHRIFROOHFWLRQ
CCICCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 28 of 39 Pharmacokinetic parameters for eteplirsen will be calculated using non -compartmental 
analysis. A ctual sampling times will be used in all final PK analyses; per protocol times 
will be used to calculate mean plasma concentrations for graphical displays. The PK 
parameters that will be determined include: Cmax, tmax, AUC, Vss, t¬Ω, CL, MRT and CLR. 
Plasma concentration -time data of eteplirsen will be used to perform a future population 
PK analysis using nonlinear mixed-effects modeling. Data may be combined with those of completed studies to support a relevant structural model. 
The details of PK analyses will be described in a separate PK SAP.  

6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRI&+$1*(6,13/$11('$1$/<6(6
&KDQJHVIURP&OLQLFDO3URWRFRO3ODQQHG$QDO\VHV
&RPSDUHGWRSURWRFROVSHFLILHGDQD O\VHVWKHFKDQJHVDUHPDGHD VIROORZV
x 

x 

x7KHREVHUYHGYDOXHVDQGFKDQJHV IURPEDVHOLQHIRUFOLQLFDOODER UDWRU\
DVVHVVPHQWVYLWDOVLJQVDQG(&* ZLOORQO\EHVXPPDUL]HGIRUED VHOLQHWKHODVW
YLVLWILQDOREVHUYDWLRQDQGWKH KLJKHVWORZHVWYDOXHV$OOF OLQLFDOODERUDWRU\
DVVHVVPHQWVYLWDOVLJQVDQG(&* UHVXOWVE\YLVLWZLOOEHLQGD WDOLVWLQJ
x7KHXQWUHDWHGSDWLHQWJURXSLVLQ WHQGHGWRHYDOXDW HWKHQDWXUDO KLVWRU\RIWKH'0'
GLVHDVHIRUSDWLHQWVZKRDUH QRWDPHQDEOHWRH[RQVNLSSLQJD QGLVQRW
FRQVLGHUHGHOLJLEOHDVDFXUUH QWFRQWUROJURXSIRUHWHSOLUVHQW UHDWHGSDWLHQWVGXHWR
WKHIROORZLQJRQO\SDWLHQW VQRWDPHQDEOHWRH[RQVNLSS LQJZHUHHQUROOHG
DVVXSSRVHGWRSODQQHGSDWLHQW VLQXQWUHDWHGJURXSXQWU HDWHGSDWLHQWVKDYH
PXFKOHVVDVVHVVPHQWIUHTXHQF\RI DGYHUVHHYHQWVGXULQJVWXG\ PRVWXQWUHDWHG
SDWLHQWVKDYHGURSSHGRX WWKHVWXG\HDUOLHU7KXVQRGLUHFWFR PSDULVRQLVPDGH
EHWZHHQHWHSOLUVHQWUHDWHGSDWLH QWVDQGXQWUHDWHGSDWLHQWV1R K\SRWKHVLVWHVWQR
SYDOXHDQGQRLQIHUHQWLDOVWDWLV WLFVZLOOEHPDGHIRUFRPSDULV RQRIHWHSOLUVHQ
WUHDWHGSDWLHQWVDQGXQW UHDWHGSDWLHQWV

x'XHWRFRPSOH[LW\RILGHQWLI\LQJ DQH[WHUQDOFRQW UROGDWDVHWW KHVWDWLVWLFDO
PHWKRGVIRUWKHLGHQ WLILFDWLRQDQGXVHRIWKH H[WHUQDOFRQWURO GDWDVHWZLOOQRWEH
GHVFULEHGLQWKLV6$3 1RDQDO\VLVRIHWHSO LUVHQWUHDWHGSDWLHQ WVDVFRPSDUHGWRDQ
H[WHUQDOFRQWUROZLOOEHSHUIRUPHG

x,IDQH[WHUQDOFRQWUROLVLGHQ WLILHGLQWKHIXWXU HWKHDQDO\VL VUHVXOWVPD\QRWEH
LQFOXGHGLQWKH&65DQGPD\EHUH SRUWHGLQDVWDQGDORQHUHSRUW 

x 





x1RRWKHUFKDQJHVDUHSODQQHGRUPDGH
&KDQJHVIURP3UHYLRXV6WDWLVWLFDO$QDO\VLV3ODQV
&RPSDUHGWRSUHYLRXV0XVFOH%LRSV \6$3WKHFKDQJHVDUHPDGHDV IROORZVCCICCI
CCI
6DUHSWD7KHUDSHXWLFV,QF
3URWRFRO 6WDWLVWLFDO$QDO\VLV3ODQ 
9HUVLRQ  3DJHRIx$UHYLVLRQRIWKHPXVFOHELRSV\6$ 3LVPDGHWRLQWHJUDWHWKHDQ DO\VHVRIPXVFOH
ELRSV\HQGSRLQWVLQWRWKLV6$3DV ILQDODQDO\VHVRIDOOHIILFDF \HQGSRLQWVIRU
VXSSRUWLQJ&65
x7KHSUHYLRXVO\SODQQHGLQWHULPDQ DO\VLVRIPXVFOHELRSV\EDVHG HQGSRLQWVZDV
QRWSHUIRUPHG
x'XHWRHYDOXDWLRQRIDQDO\WL FDOPHWKRGIRUH[RQVNLSSLQJLQ VNHOHWDOPXVFOHV
DVGHWHUPLQHGE\ W KHVWDWLVWLFDOPHWKRGRIDQDO\]LQJH[RQ VNLSSLQJLV
UHYLVHGWREHWKHVDPHDVWKHP HWKRGVIRURWKHUELRSV\EDVHGHQ GSRLQWVCCI
Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 31 of 39 7. APPENDEX 1: ABNORMAL ITIES OF INTEREST 
Appendix Table 1. Chemistry Laboratory Abnormalities of Interest 
  Predefined Change   
Test Unit Decrease  Increase Markedly Abnormal 
Criteria 
BUN mmol/L NA NA Value >1.5 √ó Baseline and 
>ULN 
Creatinine  ¬µmol/L NA 35 Value > ULN  
Sodium mmol/L 8 8 NA 
Potassium mmol/L 1.1 1.0 Value >5.5 mmol/L or  
<3 mmol/L 
Chloride mmol/L 9 8 NA 
Uric acid ¬µmol/L NA NA >1√óULN 
Calcium mmol/L 0.30 0.30 NA 
AST (SGOT)  U/L NA NA Value ‚â•2√ó Baseline Value 
and >ULN 
ALT (SGPT)  U/L NA NA Value ‚â•2√ó Baseline Value 
and >ULN 
Gamma glutamyltransferase U/L NA NA Value >3√ó Baseline Value  
and > ULN  
Alkaline phosphatase  U/L NA NA Value >1.5 √ó ULN 
Albumin g/L 10 10 < LLN or >ULN  
Total bilirubin ¬µmol/L NA 10 Value >1.5 √ó ULN 
Lactate dehydrogenase  U/L NA NA Value ‚â•2√ó Baseline Value  
Creatine phosphokinase U/L NA NA Value ‚â•2√ó Baseline Value  
Cystatin C  mg/L NA NA >ULN 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; LLN = 
lower limit of normal; NA = Not Applicable; ULN = upper limit of normal  
 
 
 
  
 
 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 32 of 39  
Appendix Table 2.  Hematology Laboratory Abnormalities of Interest 
Test Unit Markedly Abnormal Criteria  
Hematocrit  1 <LLN 
Hemoglobin g/L (or mmol/L)  <LLN 
Red blood cell count trillion/L <LLN 
White blood cell count 10^p/L >1.5 √ó ULN or <LLN  
Platelet count 10^9/L <150 or <200 with a decrease of 
at least 100  
Basophils (abs)  10^9/L >ULN or <LLN  
Eosinophils (abs)  10^9/L >1.5 √ó ULN or <LLN  
Lymphocytes (abs) 10^9/L <LLN 
Monocytes (abs) 10^9/L <LLN 
Neutrophils (abs)  10^9/L >1.5 √ó ULN or <0.000001 
abs = absolute; LLN = lower limit of normal; ULN = upper limit of normal  
Appendix Table 3.  Urinalysis Laboratory Abnormalities of Interest 
  
Test Markedly Abnormal Criteria  
Protein in urine  > 1+  
Blood in urine  Positive (+)  
RBCs in urine  >0 
Appendix Table 4. Vital Sign Abnormalities of Interest  
Variable Units Markedly Abnormal 
Criteria Lower limit  Markedly Abnormal 
Criteria Upper limit  
Systolic blood pressure mmHg <90 >140 
Diastolic blood pressure  mmHg <40 >90 
Pulse rate  beats/minute <60 >130 
Respiratory rate  breaths/min  <12 >20 
Temperature oC <36.0 >38.0 
Weight kg Decrease of 7% or 
more NA 
NA = not applicable 
 

Sarepta Therapeutics, Inc.  
Protocol 4658-203  Statistical Analysis Plan  
Version 1.0   Page 33 of 39  
Appendix Table 5. Electrocardiogram and Echocardiogram Abnormalities of  
                                Interest  
Variable Units LLN ULN Age Group 
(years) Markedly Abnormal 
Criteria 
Heart rate  Beats 
per 
minute 60 130  NA 
QTcF interval  
 
 msec 
   
 
NA  
 
NA All Screening Visit >450  
<12 >480 
‚â•12 >500 
All <320 
Increase >60  
>450 >480 
>500 
QRS interval  
 msec 
 NA NA <12 IVCD or any QRS 
conduction disturbance with 
a QRS >110 msec 
‚â•12 IVCD or any QRS 
conduction disturbance  
with a QRS >120msec 
PR interval  
 msec 
 NA NA <12 >190 
‚â•12 >220 
Left ventricular  
ejection 
fraction % NA NA All <55% 
Fractional shortening % 
NA NA All <29% 
IVCD = intraventricular conduction delay; LLN = lower limit of normal; NA = not 
applicable; QTcF= QT interval Fridericia corrected; ULN = upper limit of normal 

CCI
CCI
CCI
CCI
CCI
CCI